-+ 0.00%
-+ 0.00%
-+ 0.00%

ATYR PHARMA - EXPECTS FDA RESPONSE BY MID-SEPTEMBER 2026 FOR PHASE 3 EFZOFITIMOD STUDY

Reuters·09/01/2026 20:36:09

Please log in to view news